We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock
SEEL

Delisted

SEEL was delisted on the 15th of October, 2024.

Back to rankings

68 hedge funds and large institutions have $28M invested in Seelos Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 18 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

105% more call options, than puts

Call options by funds: $1.05M | Put options by funds: $512K

31% more capital invested

Capital invested by funds: $21.3M → $28M (+$6.69M)

30% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 10

5% more funds holding

Funds holding: 65 → 68 (+3)

39% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 18

Holders
68
Holders Change
+3
Holders Change %
+4.62%
% of All Funds
1.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
11
Reduced
18
Closed
10
Calls
$1.05M
Puts
$512K
Net Calls
+$537K
Net Calls Change
-$183K

Top Buyers

Rank Fund Capital Flow
1
MCM
MAI Capital Management
Ohio
+$743K
2
GCP
GSA Capital Partners
United Kingdom
+$114K
3
AI
AdvisorShares Investments
Maryland
+$106K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$106K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$90.4K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$979K
2
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
-$838K
3
Millennium Management
Millennium Management
New York
-$684K
4
Citadel Advisors
Citadel Advisors
Florida
-$476K
5
WP
Woodline Partners
California
-$472K
Name Holding Trade Value Shares
Change 		Change in
Stake
Qube Research & Technologies (QRT)
26
Qube Research & Technologies (QRT)
United Kingdom
$84K -$11.8K -3 -13%
Franklin Resources
27
Franklin Resources
California
$79K – – –
SFG
28
Sovereign Financial Group
Connecticut
$77K – – –
Two Sigma Investments
29
Two Sigma Investments
New York
$76K -$429K -109 -85%
Deutsche Bank
30
Deutsche Bank
Germany
$65K – – –
TAM
31
Tocqueville Asset Management
New York
$57K -$66.9K -17 -55%
SG Americas Securities
32
SG Americas Securities
New York
$56K +$55.1K +14 New
Bank of New York Mellon
33
Bank of New York Mellon
New York
$54K – – –
MFG
34
Merit Financial Group
Georgia
$52K – – –
LP
35
LMR Partners
United Kingdom
$48K – – –
AMC
36
Asset Management Corp
Illinois
$47K +$23.6K +6 +100%
Charles Schwab
37
Charles Schwab
California
$41K – – –
Wells Fargo
38
Wells Fargo
California
$40K – – –
HighTower Advisors
39
HighTower Advisors
Illinois
$37K +$11.8K +3 +50%
CFG
40
Citizens Financial Group
Rhode Island
$31K – – –
Commonwealth Equity Services
41
Commonwealth Equity Services
Massachusetts
$30K +$3.93K +1 +14%
SOW
42
State of Wyoming
Wyoming
$30K +$31.5K +8 New
CA
43
Crewe Advisors
Utah
$29K – – –
UBV
44
United Bank (Virginia)
Virginia
$27K +$27.5K +7 New
Goldman Sachs
45
Goldman Sachs
New York
$25K -$130K -33 -85%
UBS Group
46
UBS Group
Switzerland
$24K +$19.7K +5 +500%
FFG
47
Fortem Financial Group
California
$21K +$19.7K +5 New
Osaic Holdings
48
Osaic Holdings
Arizona
$20K – – –
ETC
49
Exchange Traded Concepts
Oklahoma
$17K – – –
VFA
50
Valeo Financial Advisors
Indiana
$15K – – –
1
2
3 4

SEEL Hedge Fund Activity: Q3 2022 in Review

68 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q3 2022, worth a combined $28M — up 31% from $21.3M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new SEEL positions and 10 closed out — a net gain of 3 holders — while 11 added to existing stakes and 18 trimmed.

The largest buyer was MAI Capital Management, adding an estimated $743K. The largest seller was Renaissance Technologies, cutting an estimated $979K.

  • 68 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q3 2022, up from 65 in Q2 2022.
  • Funds reported $28M of Seelos Therapeutics, Inc. Common Stock stock for Q3 2022, up 31% quarter-over-quarter.
  • 13 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q3 2022 and 10 closed out, a net change of +3 holders.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q3 2022 was MAI Capital Management, an estimated $743K added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q3 2022 was Renaissance Technologies, an estimated $979K sold.

Based on aggregated 13F filings for Q3 2022.